Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Eylea - What They Never Told You

Regeneron Stock Just Hit a 2-Year High. Here's Why.

Regeneron rallied to a two-year high as Dupixent drives strong Q3 earnings. But is there any further upside left in REGN shares? Let’s find out!

Barchart · Oct 31

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End

Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York. Speaking with Jefferies analyst Marco Baruzzi, Wessman said Alvotech ha

MarketBeat · Jun 5

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.

Benzinga · Oct 28, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.

Benzinga · Aug 1, 2025

Eylea Sales Soar, Regeneron Breaks Records with Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 Billion!

Regeneron's Q4 sales of Eylea skyrocketed to a staggering Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 billion in the U.S., sending shockwaves through the pharmaceutical industry. Incredible suc...

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Benzinga · May 2, 2022

Coverage From

Organisations

Regeneron Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Covid-19

31,230 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.